Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review.
Identifieur interne : 000063 ( Main/Exploration ); précédent : 000062; suivant : 000064Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review.
Auteurs : Lucile Grange [France] ; Philippe Guilpain [France] ; Marie-Elise Truchetet [France] ; Jean-Luc Cracowski [France]Source :
- Therapie [ 1958-5578 ]
Descripteurs français
- KwdFr :
- Anti-inflammatoires non stéroïdiens (administration et posologie), Antirhumatismaux (administration et posologie), Chloroquine (administration et posologie), Humains (MeSH), Hydroxychloroquine (administration et posologie), Incidence (MeSH), Infections à coronavirus (mortalité), Infections à coronavirus (épidémiologie), Maladies auto-immunes (traitement médicamenteux), Maladies auto-immunes (épidémiologie), Pandémies (MeSH), Pneumopathie virale (mortalité), Pneumopathie virale (épidémiologie), Rhumatismes (traitement médicamenteux), Rhumatismes (épidémiologie).
- MESH :
- administration et posologie : Anti-inflammatoires non stéroïdiens, Antirhumatismaux, Chloroquine, Hydroxychloroquine.
- mortalité : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Maladies auto-immunes, Rhumatismes.
- épidémiologie : Infections à coronavirus, Maladies auto-immunes, Pneumopathie virale, Rhumatismes.
- Humains, Incidence, Pandémies.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents, Non-Steroidal (administration & dosage), Antirheumatic Agents (administration & dosage), Autoimmune Diseases (drug therapy), Autoimmune Diseases (epidemiology), Chloroquine (administration & dosage), Coronavirus Infections (epidemiology), Coronavirus Infections (mortality), Humans (MeSH), Hydroxychloroquine (administration & dosage), Incidence (MeSH), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Pneumonia, Viral (mortality), Rheumatic Diseases (drug therapy), Rheumatic Diseases (epidemiology).
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Non-Steroidal, Antirheumatic Agents, Chloroquine, Hydroxychloroquine.
- drug therapy : Autoimmune Diseases, Rheumatic Diseases.
- epidemiology : Autoimmune Diseases, Coronavirus Infections, Pneumonia, Viral, Rheumatic Diseases.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- Humans, Incidence, Pandemics.
Abstract
Since December 2019, the COVID-19 pandemic has become a major public health problem. To date, there is no evidence of a higher incidence of COVID in patients with autoimmune rheumatic diseases and we support the approach of maintaining chronic rheumatological treatments. However, once infected there is a small but significant increased risk of mortality. Among the different treatments, NSAIDs are associated with higher rates of complications, but data for other drugs are conflicting or incomplete. The use of certain drugs for autoimmune inflammatory rheumatisms appears to be a potentially interesting options for the treatment. The rationale for their use is based on the immune system runaway and the secretion of pro-inflammatory cytokines (Il1, IL6, TNFα) in severe forms of the disease. Notably, patients on chloroquine or hydroxychloroquine as a treatment for their autoimmune rheumatic disease are not protected from COVID-19.
DOI: 10.1016/j.therap.2020.06.013
PubMed: 32665090
PubMed Central: PMC7320663
Affiliations:
- France
- Aquitaine, Auvergne-Rhône-Alpes, Languedoc-Roussillon, Nouvelle-Aquitaine, Occitanie (région administrative), Rhône-Alpes
- Bordeaux, Grenoble, Montpellier, Saint-Étienne
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review.</title><author><name sortKey="Grange, Lucile" sort="Grange, Lucile" uniqKey="Grange L" first="Lucile" last="Grange">Lucile Grange</name><affiliation wicri:level="3"><nlm:affiliation>University Saint-Étienne, 42000 Saint-Étienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Saint-Étienne, 42000 Saint-Étienne</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Saint-Étienne</settlement></placeName></affiliation></author><author><name sortKey="Guilpain, Philippe" sort="Guilpain, Philippe" uniqKey="Guilpain P" first="Philippe" last="Guilpain">Philippe Guilpain</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier's school of medicine, university Montpellier, 34967 Montpellier, France; Department of internal medicine - multi-organ diseases, local referral center for autoimmune diseases, Saint-Éloi university hospital, 34295 Montpellier, France; IRMB, Inserm U1183, CHU Montpellier, Saint-Éloi university hospital, university Montpellier, 34090 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier's school of medicine, university Montpellier, 34967 Montpellier, France; Department of internal medicine - multi-organ diseases, local referral center for autoimmune diseases, Saint-Éloi university hospital, 34295 Montpellier, France; IRMB, Inserm U1183, CHU Montpellier, Saint-Éloi university hospital, university Montpellier, 34090 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Truchetet, Marie Elise" sort="Truchetet, Marie Elise" uniqKey="Truchetet M" first="Marie-Elise" last="Truchetet">Marie-Elise Truchetet</name><affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, CHU Bordeaux, 33000 Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ. Bordeaux, CHU Bordeaux, 33000 Bordeaux</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Cracowski, Jean Luc" sort="Cracowski, Jean Luc" uniqKey="Cracowski J" first="Jean-Luc" last="Cracowski">Jean-Luc Cracowski</name><affiliation wicri:level="3"><nlm:affiliation>Univ. Grenoble Alpes, INSERM, HP2, 38000 Grenoble, France. Electronic address: Jean-Luc.Cracowski@univ-grenoble-alpes.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ. Grenoble Alpes, INSERM, HP2, 38000 Grenoble</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Jul - Aug</date><idno type="RBID">pubmed:32665090</idno><idno type="pmid">32665090</idno><idno type="doi">10.1016/j.therap.2020.06.013</idno><idno type="pmc">PMC7320663</idno><idno type="wicri:Area/Main/Corpus">000978</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000978</idno><idno type="wicri:Area/Main/Curation">000978</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000978</idno><idno type="wicri:Area/Main/Exploration">000978</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review.</title><author><name sortKey="Grange, Lucile" sort="Grange, Lucile" uniqKey="Grange L" first="Lucile" last="Grange">Lucile Grange</name><affiliation wicri:level="3"><nlm:affiliation>University Saint-Étienne, 42000 Saint-Étienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Saint-Étienne, 42000 Saint-Étienne</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Saint-Étienne</settlement></placeName></affiliation></author><author><name sortKey="Guilpain, Philippe" sort="Guilpain, Philippe" uniqKey="Guilpain P" first="Philippe" last="Guilpain">Philippe Guilpain</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier's school of medicine, university Montpellier, 34967 Montpellier, France; Department of internal medicine - multi-organ diseases, local referral center for autoimmune diseases, Saint-Éloi university hospital, 34295 Montpellier, France; IRMB, Inserm U1183, CHU Montpellier, Saint-Éloi university hospital, university Montpellier, 34090 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier's school of medicine, university Montpellier, 34967 Montpellier, France; Department of internal medicine - multi-organ diseases, local referral center for autoimmune diseases, Saint-Éloi university hospital, 34295 Montpellier, France; IRMB, Inserm U1183, CHU Montpellier, Saint-Éloi university hospital, university Montpellier, 34090 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Truchetet, Marie Elise" sort="Truchetet, Marie Elise" uniqKey="Truchetet M" first="Marie-Elise" last="Truchetet">Marie-Elise Truchetet</name><affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, CHU Bordeaux, 33000 Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ. Bordeaux, CHU Bordeaux, 33000 Bordeaux</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Cracowski, Jean Luc" sort="Cracowski, Jean Luc" uniqKey="Cracowski J" first="Jean-Luc" last="Cracowski">Jean-Luc Cracowski</name><affiliation wicri:level="3"><nlm:affiliation>Univ. Grenoble Alpes, INSERM, HP2, 38000 Grenoble, France. Electronic address: Jean-Luc.Cracowski@univ-grenoble-alpes.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ. Grenoble Alpes, INSERM, HP2, 38000 Grenoble</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author></analytic><series><title level="j">Therapie</title><idno type="eISSN">1958-5578</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Autoimmune Diseases (drug therapy)</term><term>Autoimmune Diseases (epidemiology)</term><term>Chloroquine (administration & dosage)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (mortality)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Incidence (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (mortality)</term><term>Rheumatic Diseases (drug therapy)</term><term>Rheumatic Diseases (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anti-inflammatoires non stéroïdiens (administration et posologie)</term><term>Antirhumatismaux (administration et posologie)</term><term>Chloroquine (administration et posologie)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (administration et posologie)</term><term>Incidence (MeSH)</term><term>Infections à coronavirus (mortalité)</term><term>Infections à coronavirus (épidémiologie)</term><term>Maladies auto-immunes (traitement médicamenteux)</term><term>Maladies auto-immunes (épidémiologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (mortalité)</term><term>Pneumopathie virale (épidémiologie)</term><term>Rhumatismes (traitement médicamenteux)</term><term>Rhumatismes (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Antirheumatic Agents</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires non stéroïdiens</term><term>Antirhumatismaux</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Autoimmune Diseases</term><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Autoimmune Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies auto-immunes</term><term>Rhumatismes</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies auto-immunes</term><term>Pneumopathie virale</term><term>Rhumatismes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Incidence</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Incidence</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since December 2019, the COVID-19 pandemic has become a major public health problem. To date, there is no evidence of a higher incidence of COVID in patients with autoimmune rheumatic diseases and we support the approach of maintaining chronic rheumatological treatments. However, once infected there is a small but significant increased risk of mortality. Among the different treatments, NSAIDs are associated with higher rates of complications, but data for other drugs are conflicting or incomplete. The use of certain drugs for autoimmune inflammatory rheumatisms appears to be a potentially interesting options for the treatment. The rationale for their use is based on the immune system runaway and the secretion of pro-inflammatory cytokines (Il1, IL6, TNFα) in severe forms of the disease. Notably, patients on chloroquine or hydroxychloroquine as a treatment for their autoimmune rheumatic disease are not protected from COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32665090</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1958-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>4</Issue><PubDate><MedlineDate>2020 Jul - Aug</MedlineDate></PubDate></JournalIssue><Title>Therapie</Title><ISOAbbreviation>Therapie</ISOAbbreviation></Journal><ArticleTitle>Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review.</ArticleTitle><Pagination><MedlinePgn>335-342</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0040-5957(20)30118-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.therap.2020.06.013</ELocationID><Abstract><AbstractText>Since December 2019, the COVID-19 pandemic has become a major public health problem. To date, there is no evidence of a higher incidence of COVID in patients with autoimmune rheumatic diseases and we support the approach of maintaining chronic rheumatological treatments. However, once infected there is a small but significant increased risk of mortality. Among the different treatments, NSAIDs are associated with higher rates of complications, but data for other drugs are conflicting or incomplete. The use of certain drugs for autoimmune inflammatory rheumatisms appears to be a potentially interesting options for the treatment. The rationale for their use is based on the immune system runaway and the secretion of pro-inflammatory cytokines (Il1, IL6, TNFα) in severe forms of the disease. Notably, patients on chloroquine or hydroxychloroquine as a treatment for their autoimmune rheumatic disease are not protected from COVID-19.</AbstractText><CopyrightInformation>Copyright © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grange</LastName><ForeName>Lucile</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University Saint-Étienne, 42000 Saint-Étienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guilpain</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Montpellier's school of medicine, university Montpellier, 34967 Montpellier, France; Department of internal medicine - multi-organ diseases, local referral center for autoimmune diseases, Saint-Éloi university hospital, 34295 Montpellier, France; IRMB, Inserm U1183, CHU Montpellier, Saint-Éloi university hospital, university Montpellier, 34090 Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truchetet</LastName><ForeName>Marie-Elise</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, CHU Bordeaux, 33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cracowski</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Univ. Grenoble Alpes, INSERM, HP2, 38000 Grenoble, France. Electronic address: Jean-Luc.Cracowski@univ-grenoble-alpes.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>French Society of Pharmacology and Therapeutics</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Therapie</MedlineTA><NlmUniqueID>0420544</NlmUniqueID><ISSNLinking>0040-5957</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="N">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dexamethasone</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Pharmacology</Keyword><Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">Rheumatology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32665090</ArticleId><ArticleId IdType="pii">S0040-5957(20)30118-9</ArticleId><ArticleId IdType="doi">10.1016/j.therap.2020.06.013</ArticleId><ArticleId IdType="pmc">PMC7320663</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Auvergne-Rhône-Alpes</li><li>Languedoc-Roussillon</li><li>Nouvelle-Aquitaine</li><li>Occitanie (région administrative)</li><li>Rhône-Alpes</li></region><settlement><li>Bordeaux</li><li>Grenoble</li><li>Montpellier</li><li>Saint-Étienne</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Grange, Lucile" sort="Grange, Lucile" uniqKey="Grange L" first="Lucile" last="Grange">Lucile Grange</name></region><name sortKey="Cracowski, Jean Luc" sort="Cracowski, Jean Luc" uniqKey="Cracowski J" first="Jean-Luc" last="Cracowski">Jean-Luc Cracowski</name><name sortKey="Guilpain, Philippe" sort="Guilpain, Philippe" uniqKey="Guilpain P" first="Philippe" last="Guilpain">Philippe Guilpain</name><name sortKey="Truchetet, Marie Elise" sort="Truchetet, Marie Elise" uniqKey="Truchetet M" first="Marie-Elise" last="Truchetet">Marie-Elise Truchetet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000063 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000063 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32665090
|texte= Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32665090" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |